

Electronic Acknowledgement Receipt

EFS ID:	3918148
Application Number:	10042644
International Application Number:	
Confirmation Number:	7691
Title of Invention:	Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
First Named Inventor/Applicant Name:	Jacques F. Banchereau
Customer Number:	45473
Filer:	Thomas E. Holsten/Lori Aboulmouna
Filer Authorized By:	Thomas E. Holsten
Attorney Docket Number:	13786-7
Receipt Date:	10-SEP-2008
Filing Date:	08-JAN-2002
Time Stamp:	14:55:35
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1860
RAM confirmation Number	196
Deposit Account	231925
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		13786_7_RCE_EOT_IDS.pdf	524652 b47391e47e75a92178295e5d11f8ae9e6033f31e	yes	9
	Multipart Description/PDF files in .zip description				
	Document Description		Start		End
	Request for Continued Examination (RCE)		1		1
	Extension of Time		2		2
	Amendment Submitted/Entered with Filing of CPA/RCE		3		3
	Claims		4		4
	Applicant Arguments/Remarks Made in an Amendment		5		7
	Information Disclosure Statement Letter		8		8
	Information Disclosure Statement (IDS) Filed (SB/08)		9		9
Warnings:					
Information:					
2	NPL Documents	Bennett_2003_interferon_and_granulopoiesis_signatures.pdf	1778947 1db9de2917c50ec11f611856fce9bfc1e83d3582	no	16
Warnings:					
Information:					
3	NPL Documents	Kawade_1985_the_nature_of_neutralization.pdf	1192844 7f911261d3eec282de0490c01a9d534687b51d8e	no	9
Warnings:					
Information:					
4	NPL Documents	Kontsek_1991_enhancement_of_neutralizing_efficacy.pdf	621176 50fc0a34dda74e9bc53df09dc9cfd658545793	no	6
Warnings:					
Information:					

5	NPL Documents	Mathain_2004_IFN_alpha_induces_early_lethal_lupus.pdf	1803721	no	10
Warnings:					
Information:					
6	NPL Documents	Meager_1997_natural_autoantibodies_to_interferon.pdf	459703	no	5
Warnings:					
Information:					
7	NPL Documents	Pascual_2003_the_central_role_of_interferon_in_lupus.pdf	1535561	no	11
Warnings:					
Information:					
8	NPL Documents	Preble_1982_Systematic_lupus_serology.pdf	1135941	no	5
Warnings:					
Information:					
9	NPL Documents	Raanani_2002_immune_mediated_complications.pdf	1771398	no	14
Warnings:					
Information:					
10	NPL Documents	Santini_Type_I_Interferon_as_a_Powerful_Adjuvant_for_Monoclonal_Antibody_Derived_Peptides.pdf	2325997	no	22
Warnings:					
Information:					
11	NPL Documents	Shearer_1984_monoclonal_antibodies.pdf	1413741	no	8
Warnings:					
Information:					
12	NPL Documents	Weber_1987_Single_amino_acid_antigen_recognition.pdf	918601	no	9
Warnings:					
Information:					
13	NPL Documents	PAQUETTE_Interferon_alpha_gamma_induced_human_natural_killer_cell_activation.pdf	1238993	no	10
Warnings:					
Information:					

14	Fee Worksheet (PTO-06)	fee-info.pdf	32024 d06fe4766cc745296a7ba431f22e32c8903961d0	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			16753299		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					